Hostname: page-component-7b7567c8c-wxvwp Total loading time: 0 Render date: 2026-11-15T00:45:46.643Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of targeted intervention using a collaborative approach for oral third-generation cephalosporins: An interrupted time-series analysis

Published online by Cambridge University Press:  11 July 2022

Ryo YamaguchiOpen the ORCID record for Ryo Yamaguchi[Opens in a new window],
Koh OkamotoOpen the ORCID record for Koh Okamoto[Opens in a new window],
Takehito YamamotoOpen the ORCID record for Takehito Yamamoto[Opens in a new window],
Sohei HaradaOpen the ORCID record for Sohei Harada[Opens in a new window],
Takehiro Tanaka,
Hiroshi SuzukiOpen the ORCID record for Hiroshi Suzuki[Opens in a new window] and
Kyoji Moriya
Ryo Yamaguchi
Affiliation:
Department of Pharmacy, the University of Tokyo Hospital, Tokyo, Japan
Koh Okamoto*
Affiliation:
Department of Infectious Diseases, the University of Tokyo Hospital, Tokyo, Japan
Takehito Yamamoto
Affiliation:
Department of Pharmacy, the University of Tokyo Hospital, Tokyo, JapanThe Education Center for Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, the University of Tokyo, Tokyo, Japan
Sohei Harada
Affiliation:
Department of Infection Control and Prevention, Faculty of Medicine, the University of Tokyo Hospital, Tokyo, Japan
Takehiro Tanaka
Affiliation:
Department of Pharmacy, the University of Tokyo Hospital, Tokyo, Japan
Hiroshi Suzuki
Affiliation:
Department of Pharmacy, the University of Tokyo Hospital, Tokyo, Japan
Kyoji Moriya
Affiliation:
Department of Infectious Diseases, the University of Tokyo Hospital, Tokyo, JapanDepartment of Infection Control and Prevention, Faculty of Medicine, the University of Tokyo Hospital, Tokyo, Japan
*
Author for correspondence: Koh Okamoto, Department of Infectious Diseases, the University of Tokyo Hospital, Hongo 7-3-1, Bunkyo-ku, Tokyo, 113-8655 Japan. E-mail: kokamoto-tky@umin.ac.jp

Abstract

Objectives:

To assess the effectiveness of a targeted intervention using a collaborative approach, added to a comprehensive educational intervention, to facilitate the appropriate use of oral third-generation cephalosporins (3GCs).

Design:

Quasi-experimental study.

Setting:

The University of Tokyo Hospital, a tertiary-care teaching hospital.

Participants:

Approximately 2,000,000 outpatients and 80,000 inpatients at the hospital between April 2017 and March 2020.

Intervention:

The targeted intervention using the collaborative approach was implemented in the departments with the highest use of oral 3GCs (ophthalmology and dermatology departments). Interrupted time-series analysis was applied to assess the change in days of therapy (DOT) of oral 3GCs between the preintervention period (April 2017–April 2019) and the postintervention period (May 2019–March 2020) for both inpatients and outpatients.

Results:

After the introduction of the targeted intervention with oral 3GCs, a significant immediate reduction of 13.48 DOT per 1,000 patient days was detected in inpatients (P < .001). However, no significant change in slope was observed before and after the intervention (−0.02 DOT per 1,000 patient days per month; P = .94). Although a temporary increase was observed after the targeted intervention in outpatients, the slope significantly decreased (−0.69 DOT per 1,000 outpatient visits per month; P = .044). No differences were observed in the use of other oral antibiotics after the intervention.

Conclusions:

The targeted intervention contributed to a reduction in DOT of oral 3GCs in both inpatients and outpatients. Targeted interventions using a collaborative approach might be helpful in further decreasing the inappropriate use of antibiotics.

Information

Type
Original Article
Information
Antimicrobial Stewardship & Healthcare Epidemiology , Volume 2 , Issue 1 , 2022, e115
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America.

Inappropriate antimicrobial agent use contributes to the increase of antimicrobial resistance (AMR). 1 Antimicrobial stewardship promotes appropriate use, optimizes treatment efficacy, and minimizes adverse events associated with antibiotic use. Reference Barlam, Cosgrove and Abbo2 Several antimicrobial stewardship interventions have been proposed and they vary depending on the setting, target prescriber range, target antimicrobials, target infection or syndrome, and approach. 3,Reference Sanchez, Fleming-Dutra, Roberts and Hicks4 Among various interventions, prospective audit and feedback (PAF), also known as handshake stewardship in face-to-face meetings and discussions, is a collaborative approach that has been effective and commonly integrated into intervention implementation. Reference Hurst, Child, Pearce, Palmer, Todd and Parker5 Although effective, handshake stewardship can be very laborious, which hampers its implementation. Reference Barlam, Cosgrove and Abbo2,Reference MacBrayne, Williams and Levek6 Therefore, interventions must be tailored for the available resources and areas requiring improvements at each facility.

The World Health Organization (WHO) reported that oral antibiotics were the most consumed antibiotics (96%–98%) in most countries. 7–9 The consumption of oral third-generation cephalosporins (3GCs) has been particularly high in Japan compared to European countries or the United States. Reference Muraki, Yagi and Tsuji10–12 Oral 3GCs are a class of broad-spectrum antibiotics; however, their role in clinical practice remains limited given their poor bioavailability. Reference Grayson, Crowe and McCarthy13 Furthermore, cephalosporins have been associated with increased risk for Clostridioides difficile infections (CDI), Reference Slimings and Riley14 and there is concern that their inappropriate use may accelerate the emergence of AMR. Reference Sanchez, Fleming-Dutra, Roberts and Hicks4,15 Hence, the Japanese government launched the National Action Plan (NAP) on AMR, which included an outcome index requiring that the daily use of oral cephalosporins (including oral 3GCs, quinolones, and macrolides) be reduced per 1,000 inhabitants by 50% in 2020 from the 2013 level. 16 Consequently, we began comprehensive prescriber education using hospital guidelines on the appropriate use of antibiotics and lectures by an infectious disease (ID) clinical pharmacist on antimicrobial stewardship, targeting inpatient and outpatient oral antibiotic use by all physicians in our hospital in 2017. However, the goal of reducing the use of oral 3GCs was not achieved, indicating that further effective interventions are necessary to further decrease the use of oral 3GCs.

In this study, we adopted a collaborative approach in which we first identified the unmet needs of prescribers and tried to solve their problems and then assessed the effectiveness of our collaborative approach for oral 3GCs combined with comprehensive educational intervention.

Methods

Study design and setting

We conducted a quasi-experimental study at the University of Tokyo Hospital (UTH), Tokyo, Japan, between April 2017 and March 2020. UTH is a tertiary-care teaching hospital with 1,226 beds and ∼700,000 annual outpatient visits and ∼27,000 annual inpatient admissions. Physicians can consult ID specialists at any time.

We included all inpatients and outpatients during the study period and investigated the antimicrobial consumption by department. To assess the impact of the targeted intervention for oral 3GC consumption, antibiotic use before (phase 1: April 2017–April 2019) and after the targeted intervention (phase 2: May 2019–March 2020) was compared using interrupted time-series (ITS) analysis (Appendix 1). The available oral 3GCs at UTH included cefcapene-pivoxil (CFPN-PI), cefditoren-pivoxil, cefpodoxime-proxetil, and cefdinir. The Institutional Review Board and Ethics Committee of the Graduate School of Medicine and Faculty of Medicine, University of Tokyo, approved the study protocol (approval no. 2020171NI, 2529) and waived the need for patients’ written informed consent. This study was conducted according to the ethical standards specified in the 1964 Declaration of Helsinki and its later amendments.

Phase 1 (April 2017–April 2019): Comprehensive intervention for all oral antibiotics

At UTH, a multidisciplinary antimicrobial stewardship team (AST) was established in April 2015 to promote the appropriate use of antibiotics by implementing programs for the entire hospital. The AST, consisting of ID specialists, clinical pharmacists, and clinical microbiologists, has been performing daily PAF since April 2015 for patients treated with anti–methicillin-resistant Staphylococcus aureus agents or carbapenems.

The AST commenced comprehensive interventions for oral antibiotics usage in June 2017 (1) by incorporating the government guidelines, where antibiotics are mostly not indicated for common cold and gastrointestinal infections, into the institutional guidelines; (2) by sending an annual usage report on oral cephalosporins, quinolones, and macrolides for each department to all clinical departments; and (3) by providing online learning materials for all medical staff (Table 1).

Table 1.

Description of Comprehensive Intervention for Oral Antibiotics

Note. AMR, antimicrobial resistance; ID, infectious disease.

Phase 2 (May 2019– March 2020): Targeted intervention for oral 3GCs

In phase 1, we confirmed that the comprehensive intervention reduced the annual 3GC use by 11% among inpatients and 17% among outpatients in 2017 compared to 2016, although the Japanese NAP goal of 50% reduction was not achieved. The departments of ophthalmology (inpatients) and dermatology (outpatients) were identified as the top oral 3GC users; therefore in 2017, the following tailored interventions were executed to facilitate further reduction of oral 3GC use.

For the ophthalmology department, we audited oral 3GC use in inpatients and found that CFPN-PI was routinely prescribed for 3 days (from the day of surgery) after cataract surgery. Although perioperative oral antibiotics, including CFPN-PI, have been used in Japan for prophylaxis against various infections, including ocular infections, data on its clinical efficacy and aqueous humor penetration were lacking. Reference Inoue, Uno, Usui, Kobayakawa, Ichihara and Ohashi17 After multiple discussions with the ophthalmology department, we conducted clinical research in collaboration with them to evaluate the aqueous humor penetration of orally administered CFPN-PI. The results showed that oral CFPN-PI poorly penetrated the aqueous humor. Reference Okamoto, Asano and Yamamoto18 Because CFPN-PI is very unlikely to be effective in preventing endophthalmitis after cataract surgery, it was removed from the order set by April 2019 (without any alternative antibiotics).

For the dermatology department, we provided a one-time face-to-face lecture in April 2019. To ensure effectiveness, we first had discussions with an attending dermatologist in charge of clinical care on how to best deliver our message to all the members in the dermatology department with various levels of experience. According to the advice from the attending dermatologist, we asked the dermatologists (∼30 physicians, including attending physicians and physicians in training) to complete a questionnaire to provide information on their understanding and raise questions on the use of oral 3GCs and other antibiotics in their field. We then provided a face-to-face lecture specifically addressing their questions and concerns. The lecture covered the background, strategies against AMR, AMR action plan in Japan, appropriate use of antibiotics in dermatology, prevention of surgical site infections, and remedial education on UTH guidelines for appropriate antibiotic use. During the lecture, questions were encouraged, raised, and answered. We received questions even after the lecture, which we answered.

Outcome

The primary outcome was days of therapy (DOT) of oral 3GCs in inpatients and outpatients. For inpatients, the amount of antibiotics used was evaluated by recording the DOT per 1,000 patient days (DOT/1,000 PD). Reference Polk, Fox, Mahoney, Letcavage and MacDougall19 For outpatient, the total number of outpatient visits per month was the denominator, and DOT per 1,000 outpatient visits (DOT/1,000 OV) were calculated according to previous reports. Reference Uda, Kimura and Nishimura20 Antibiotics were classified according to the WHO Anatomical Therapeutic Chemical classification system. Reference Hutchinson, Patrick and Marra21 Secondary outcomes included (1) DOT of other oral antibiotics (penicillins, other cephalosporins, fluoroquinolones, and macrolides) in inpatients and outpatients; (2) DOT of intravenous antibiotics; and (3) incidence of hospital-acquired CDI (HA-CDI) calculated as the number of inpatients with laboratory-confirmed C. difficile toxin production ≥72 h after hospital admission. Patients with multiple C. difficile toxin-production detections were only counted once. We confirmed C. difficile toxin production using the GE immunochromato-CD GDH/TOX test (Nissui, Tokyo, Japan).

Statistical analysis

The Mann-Whitney U test was used for continuous variables. Details of the ITS analysis are described in Appendix 1. All statistical analyses were performed using IBM SPSS Statistics version 24 software (IBM, Armonk, NY), and statistical significance was set at P < .05.

Results

During the study period, there were ∼2,000,000 outpatient visits and ∼80,000 hospital admissions, with no major changes in the number of outpatient visits, hospital admissions, and length of hospital stay. Data on the overall incidence of surgical site infections or complications from surgery were unavailable.

Trends in oral 3GC use

Regarding DOT/1,000 PD for oral 3GCs in inpatients, there was a statistically significant decrease in the trend by 0.44 DOT/1,000 PD/month (P < .001) in phase 1 for all departments (Fig. 1A and Table 2). After the targeted intervention, there was a significant immediate reduction by 13.48 DOT/1,000 PD (P < .001). However, no significant change in slope was observed between the 2 phases. In the ophthalmology department, there was no significant trend change during phase 1 (Fig. 1B and Table 2). After the targeted interventions, there was a statistically significant immediate reduction (−518.32 DOT/1,000 PD; P < .001), with the ophthalmology department accounting for ∼80% of the reduction. However, there was no significant change in the slope. For the dermatology department, there was a significant decreasing trend (−0.78 DOT/1,000 PD/month; P = .035) during phase 1 (Fig. 1C and Table 2). After the targeted intervention, there were no significant changes in both levels and slope between the 2 phases.

Fig 1.

Segmented linear regression of oral third-generation cephalosporins (3GCs) days of therapy (DOT) per 1000 patient days in inpatients, before and after the targeted intervention. (A) All departments. (B) Ophthalmology. (C) Dermatology.

Table 2.

Interrupted Time-Series Analysis of Oral Third-Generation Cephalosporins for Inpatients in 3 Groups

Note. CI, confidence interval.

Regarding DOT/1,000 OV for oral 3GCs in outpatients, there was a statistically significant decreasing trend (−1.16 DOT/1,000 OV/month; P < .001) during phase 1 for all departments (Fig. 2A and Table 3). After the targeted intervention, an immediate increase was observed (7.67 DOT/1,000 OV; P = .002), and the slope significantly decreased (−0.69 DOT/1,000 OV/month; P = .044). For the ophthalmology department, there was a significant decrease in trend (−8.78 DOT/1,000 OV/month; P < .001) during phase 1 (Fig. 2B and Table 3). For the dermatology department, there was no significant decrease in trend during phase 1 (Fig. 2C and Table 3). After the targeted intervention, there was no significant change in levels, but the slope significantly decreased (−6.90 DOT/1,000 OV/month; P = .01).

Fig 2.

Segmented linear regression of oral third-generation cephalosporins (3GCs) days of therapy (DOT) per 1,000 outpatient visits among outpatients, before and after the targeted intervention. (A) All departments. (B) Ophthalmology. (C) Dermatology.

Table 3.

Interrupted Time-Series Analysis of Oral Third-Generation Cephalosporins for Outpatients in 3 Groups

Note. CI, confidence interval.

Contrary to the observed decreases in oral 3GC use, no statistically significant increases were observed in the use of other oral or intravenous antibiotics (Table 4).

Table 4.

Interrupted Time-Series Analysis for Hospital-wide Antimicrobial Consumption

Note. 1GC, first-generation cephalosporins; CI, confidence interval; IV, intravenous.

CDI

HA-CDI incidence was not statistically different between phases 1 and 2 (0.34 vs 0.33 per 1,000 PD; P = .19).

Discussion

We evaluated the effectiveness of targeted intervention using a collaborative approach for oral 3GCs by assessing time-series changes in antimicrobial use before and after the intervention. We detected a significant immediate reduction in 3GC use in inpatients, and the slope significantly decreased in outpatients after the targeted intervention. We achieved a 50% reduction in the DOT of oral 3GCs, the goal of Japanese NAP; however, the use of other oral antibiotics and HA-CDI incidence remained largely unchanged.

In the present study, a hospital-wide educational intervention was provided to all prescribers of oral antimicrobials, focusing on 3 antimicrobial classes (cephalosporins, quinolones, and macrolides) in phase 1. Although a certain degree of reduction was observed, the target was not achieved. Previous reports showed that educational interventions optimized antimicrobial use, but this intervention alone was inadequate. Thus, unidirectional education, such as lectures or informational pamphlets, should be used to complement other stewardship activities. Reference Davey, Brown and Charani22,Reference Landgren, Harvey, Mashford, Moulds, Guthrie and Hemming23 Therefore, we added an intervention targeted at a specific department using a collaborative approach in phase 2. It was a behavioral science-based intervention Reference Sikkens, van Agtmael and Peters24 with a collaborative approach to support prescriber behavioral change and resulted in decreased oral 3GC use (Tables 2 and 3). Furthermore, the results of the sensitivity analyses (Appendix 2 and Supplementary Table 1) revealed that the targeted intervention to the ophthalmology and dermatology departments affected the hospital-wide use of oral 3GCs in inpatients and outpatients, respectively. Uda et al Reference Uda, Kimura and Nishimura20 reported that educational intervention against inappropriate oral 3GC use decreased DOT without affecting patients’ clinical outcomes. However, to the best of our knowledge, this is the first report to show that the addition of a department-specific targeted collaborative approach to hospital-wide education further reduces oral 3GC use.

There are several barriers to changing physicians’ antimicrobial prescription behaviors. First, basic education on the appropriate use of antimicrobial agents tends to be conceptual (eg, “as narrow as possible”) and unidirectional. Therefore, it is difficult for clinicians to view it as knowledge that is readily applicable to daily practice. Second, physicians often dismiss the long-term benefit of the appropriate use of antimicrobials, that is, the prevention of the development of bacterial resistance. Reference Hoffmann and Del Mar25 Third, physicians’ knowledge outside their expertise often remains outdated. Therefore, it may be difficult to encourage physicians to change their individual behavior through unidirectional education alone. Hence, we hypothesized that addressing their unique problems and needs and solving them collaboratively can have a crucial impact. In our study, analysis of the prescribing patterns and questionnaires revealed routine order sets in the ophthalmology department and a lack of knowledge on the common causative organisms of skin infections.

In the dermatology department, the corresponding spectrum of antimicrobial agents was the main driver for the physicians’ prescribing patterns. Therefore, we provided a one-time face-to-face lecture for dermatologists to resolve knowledge gaps and follow-up after the lecture, which may have led to a reduction in the consumption of oral 3GCs in the dermatology department. Interestingly, time profiles of DOT in inpatients and outpatients in the dermatology department showed different patterns: a significant decreasing trend during phase 1 and nonsignificant change in slope between phases 1 and 2 in inpatients (Fig. 1C), and a nonsignificant decreasing trend in phase 1 and a significant change in slope between phases 1 and 2 in outpatients (Fig 2C). This observation may be explained by the difference in the physicians’ experience between inpatients and outpatients. We hypothesize that the intervention provided in phase 1 focusing on general issues was effective enough to reduce inappropriate prescription because many junior physicians (including residents) directly care for inpatients. However, the targeted intervention, which was relatively advanced in contents, may have been less effective for junior physicians, and, consequently, no significant slope change was observed between phases 1 and 2. Conversely, since senior physicians directly care for outpatients, most of them already understood the contents of the intervention in phase 1; thus, no significant downward trend was observed in phase 1. In contrast, the contents of the targeted intervention were informative even to senior physicians, and this may have led to the significant change in slope between phases 1 and 2.

We did not ask or force the ophthalmology department to remove the oral 3GCs from the order set; instead, we had an open discussion with them to revisit the role of prophylaxis with oral 3GCs, which led to a collaborative clinical study. Reference Okamoto, Asano and Yamamoto18 Based on this study’s results, the ophthalmology department removed CFPN-PI from the prophylaxis regimen. Several studies reported that interventions focusing on facility-specific order sets and guidelines can optimize antimicrobial use. Reference Barlam, Cosgrove and Abbo2,Reference Carratalà, Garcia-Vidal and Ortega26,Reference Bozkurt, Kaya and Gulsun27 A review of the order set targeting specific departments with high use of antibiotics may bring about a high return because a collaborative approach can easily be adopted without much human resource. Additionally, the completion of a questionnaire to identify areas of input by prescribers may help foster more effective education. Such multifaceted educational methods contribute to the reduction of antimicrobial use. Reference Butler, Simpson and Dunstan28 Our findings reinforce the importance of addressing the barriers specific to individual groups and tailoring interventions accordingly. Although we focused on oral 3GCs, the findings of this study may apply to other antibiotics and settings.

Notably, inpatients and outpatients showed different time profiles of DOT of oral 3GCs; especially, a statistically significant immediate increase in level was observed only in outpatients (7.67 DOT/1,000 PD; P = .002) (Table 3). Because no immediate increase in levels was observed in either the ophthalmology or the dermatology department (Fig. 2 and Table 3), it is unlikely that targeted interventions for these departments directly affected the observed immediate increase in levels in all departments. During the study periods, only general interventions were implemented in all departments other than the ophthalmology and dermatology departments. Additionally, the timing of the targeted interventions in the ophthalmology and dermatology departments overlapped with the timing of physician turnover at UTH when the educational effects of the general interventions are reset. Therefore, antimicrobial use may have been temporarily inappropriate at this time in all departments other than the ophthalmology and dermatology departments, and, consequently, a significant immediate increase in levels may have been observed.

Previous studies showed that the implementation of antimicrobial stewardship significantly reduced the incidence of HA-CDI in hospitals. Reference Baur, Gladstone and Burkert29,Reference Valiquette, Cossette, Garant, Diab and Pépin30 However, we observed no significant reduction in the incidence of HA-CDI after the targeted intervention. This is clinically plausible because the baseline incidence of HA-CDI in our hospital was lower than that in other Japanese hospitals. Reference Kato, Senoh and Honda31 Furthermore, the incidence of CDI is influenced by various factors other than antimicrobial use, such as adherence to infection control behaviors. Reference Ananthakrishnan32 Moreover, the use of other antibiotics in relation to HA-CDI, such as the second- and fourth-generation cephalosporins, penicillins, and fluoroquinolones, did not change. Reference Leffler and Lamont33 Additional interventions are needed to further decrease HA-CDI.

This study had several limitations. We did noy employ a control group, and the ITS analysis design did not allow us to rule out confounding by cointerventions or other events that occurred during the intervention. However, to the best of our knowledge, there was no major change in practice or patient population that could have directly affected oral antibiotic prescription at UTH during the study period. By the end of the study period, coronavirus disease 2019 (COVID-19) had not spread widely in Japan, and UTH cared for only 1 patient with COVID-19. Therefore, the COVID-19 pandemic appears to have had little impact on antibiotic use at UTH during the study period. This study was conducted at a single center in Japan and it had a before-and-after comparative design. Thus, caution is required when interpreting our findings. Because the problems related to inappropriate antimicrobial use vary between facilities, individualized approaches are needed. However, as discussed above, targeted interventions using a collaborative approach may work well in other facilities and may be viable options to further decrease the use of specific antibiotics of concern. The long-term sustainability of the effects of our interventions was not assessed. The effect of education may gradually wane because of physician turnover; thus, regular interventions might be necessary for the long-term suppression of inappropriate antibiotic use. The drivers of the observed changes, perhaps through a qualitative study in the future should be further evaluated.

In conclusion, our study demonstrated the usefulness of targeted interventions using a collaborative approach against oral 3GCs combined with comprehensive interventions. We believe that targeted interventions using a collaborative approach may be helpful in further decreasing the inappropriate use of antibiotics.

Supplementary material

To view supplementary material for this article, please visit https://doi.org/10.1017/ash.2022.251

Acknowledgments

Financial support

No financial support was provided relevant to this article.

Conflicts of interest

R.Y. reports personal fees from MSD and Shionogi. K.O. reports personal fees from AstraZeneca, Sanyo Chemical, Kyorin Pharmaceuticals, Ono Pharmaceutical, and Astellas. S.H. reports personal fees from FUJIFILM Toyama Chemical, BD, Meiji, Shionogi, Sumitomo Dainippon Pharma, MSD, Daiichi Sankyo, and NISSUI PHARMACEUTICAL, and received grants from MSD and Shionogi outside the submitted work. H.S. has received grants from Pfizer Japan Inc and Sawai Pharmaceutical. All other authors declare no conflicts of interest relevant to this article.

References

Antibiotic resistance threats in the United States, 2019. Centers for Disease Control and Prevention website. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Published 2019. Accessed December 2, 2021.Google Scholar
Barlam, TF, Cosgrove, SE, Abbo, LM, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62:e51–e77.CrossRefGoogle Scholar
Core elements of hospital antibiotic stewardship programs. Centers for Disease Control and Prevention website. https://www.cdc.gov/antibiotic-use/core-elements/hospital.html. Published 2019. Accessed December 2, 2021.Google Scholar
Sanchez, GV, Fleming-Dutra, KE, Roberts, RM, Hicks, LA. Core elements of outpatient antibiotic stewardship. MMWR Recomm Rep 2016;65:1–12.CrossRefGoogle ScholarPubMed
Hurst, AL, Child, J, Pearce, K, Palmer, C, Todd, JK, Parker, SK. Handshake stewardship: a highly effective rounding-based antimicrobial optimization service. Pediatr Infect Dis J 2016;35:1104–1110.CrossRefGoogle ScholarPubMed
MacBrayne, CE, Williams, MC, Levek, C, et al. Sustainability of handshake stewardship: extending a hand is effective years later. Clin Infect Dis 2020;70:2325–2332.CrossRefGoogle Scholar
WHO report on surveillance of antibiotic consumption: 2016–2018 early implementation. World Health Organization website. https://www.who.int/publications/i/item/who-report-on-surveillance-of-antibiotic-consumption. Published 2018. Accessed June 27, 2022.Google Scholar
English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) Report 2019–2020. Public Health England website. https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report. Published November 2020. Accessed 12 October 2021.Google Scholar
Outpatient antibiotic prescriptions. Centers for Disease Control and Prevention website. https://www.cdc.gov/antibiotic-use/community/pdfs/annual-reportsummary_2014.pdf. Published 2014. Accessed December 2, 2021.Google Scholar
Muraki, Y, Yagi, T, Tsuji, Y, et al. Japanese antimicrobial consumption surveillance: first report on oral and parenteral antimicrobial consumption in Japan (2009–2013). J Glob Antimicrob Resist 2016;7:19–23.CrossRefGoogle Scholar
Goossens, H, Ferech, M, Coenen, S, Stephens, P. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis 2007;44:1091–1095.CrossRefGoogle ScholarPubMed
Surveillance of antimicrobial consumption in Europe, 2013–2014. European Centre for Disease Prevention and Control website. https://www.ecdc.europa.eu/sites/default/files/documents/Surveillance-antimicrobial-consumption-Europe-ESAC-Net-2013-14.pdf. Published May 2018. Accessed December 2, 2021.Google Scholar
Grayson, ML, Crowe, SM, McCarthy, JS, et al. Kucers’ The Use of Antibiotics Sixth Edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs. Boca Raton, FL: CRC Press; 2010.CrossRefGoogle Scholar
Slimings, C, Riley, TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69:881–891.CrossRefGoogle ScholarPubMed
Antimicrobial resistance. World Health Organization website. https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance. Published 17 November 2021. Accessed December 2, 2021.Google Scholar
National action plan on antimicrobial resistance (AMR) 2016–2020. The Government of Japan Ministry of Health website. https://www.mhlw.go.jp/file/06-Seisakujouhou-10900000-Kenkoukyoku/0000138942.pdf. Published April 2016. Accessed December 2, 2021.Google Scholar
Inoue, T, Uno, T, Usui, N, Kobayakawa, S, Ichihara, K, Ohashi, Y. Incidence of endophthalmitis and the perioperative practices of cataract surgery in Japan: Japanese Prospective Multicenter Study for Postoperative Endophthalmitis after Cataract Surgery. Jpn J Ophthalmol 2018;62:24–30.CrossRefGoogle ScholarPubMed
Okamoto, K, Asano, S, Yamamoto, T, et al. Poor penetration of cefcapene into aqueous humor after oral administration of cefcapene pivoxil to patients undergoing cataract surgery. J Infect Chemother 2020;26:312–315.CrossRefGoogle ScholarPubMed
Polk, RE, Fox, C, Mahoney, A, Letcavage, J, MacDougall, C. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007;44:664–670.CrossRefGoogle ScholarPubMed
Uda, A, Kimura, T, Nishimura, S, et al. Efficacy of educational intervention on reducing the inappropriate use of oral third-generation cephalosporins. Infection 2019;47:1037–1045.CrossRefGoogle ScholarPubMed
Hutchinson, JM, Patrick, DM, Marra, F, et al. Measurement of antibiotic consumption: a practical guide to the use of the anatomical therapeutic chemical classification and defined daily dose system methodology in Canada. Can J Infect Dis 2004;15:29–35.Google Scholar
Davey, P, Brown, E, Charani, E, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database Syst Rev 2013:CD003543.CrossRefGoogle Scholar
Landgren, FT, Harvey, KJ, Mashford, ML, Moulds, RF, Guthrie, B, Hemming, M. Changing antibiotic prescribing by educational marketing. Med J Aust 1988;149:595–599.CrossRefGoogle ScholarPubMed
Sikkens, JJ, van Agtmael, MA, Peters, EJG, et al. Behavioral approach to appropriate antimicrobial prescribing in hospitals: the Dutch Unique Method for Antimicrobial Stewardship (DUMAS) Participatory Intervention Study. JAMA Intern Med 2017;177:1130–1138.CrossRefGoogle ScholarPubMed
Hoffmann, TC, Del Mar, C. Clinicians’ expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern Med 2017;177:407–419.CrossRefGoogle ScholarPubMed
Carratalà, J, Garcia-Vidal, C, Ortega, L, et al. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial. Arch Intern Med 2012;172:922–928.CrossRefGoogle Scholar
Bozkurt, F, Kaya, S, Gulsun, S, et al. Assessment of perioperative antimicrobial prophylaxis using ATC/DDD methodology. Int J Infect Dis 2013;17:e1212–e1217.CrossRefGoogle ScholarPubMed
Butler, CC, Simpson, SA, Dunstan, F, et al. Effectiveness of multifaceted educational programme to reduce antibiotic dispensing in primary care: practice-based randomised controlled trial. BMJ 2012;344:d8173.CrossRefGoogle ScholarPubMed
Baur, D, Gladstone, BP, Burkert, F, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. Lancet Infect Dis 2017;17:990–1001.CrossRefGoogle ScholarPubMed
Valiquette, L, Cossette, B, Garant, MP, Diab, H, Pépin, J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile–associated disease caused by the hypervirulent NAP1/027 strain. Clin Infect Dis 2007;45 Suppl 2:S112–S121.CrossRefGoogle Scholar
Kato, H, Senoh, M, Honda, H, et al. Clostridioides (Clostridium) difficile infection burden in Japan: a multicenter prospective study. Anaerobe 2019;60:102011.CrossRefGoogle ScholarPubMed
Ananthakrishnan, AN. Clostridium difficile infection: epidemiology, risk factors, and management. Nat Rev Gastroenterol Hepatol 2011;8:17–26.CrossRefGoogle ScholarPubMed
Leffler, DA, Lamont, JT. Clostridium difficile infection. N Engl J Med 2015;372:1539–1548.CrossRefGoogle ScholarPubMed
Figure 0

Table 1.Description of Comprehensive Intervention for Oral Antibiotics

Figure 1

Fig 1.Segmented linear regression of oral third-generation cephalosporins (3GCs) days of therapy (DOT) per 1000 patient days in inpatients, before and after the targeted intervention. (A) All departments. (B) Ophthalmology. (C) Dermatology.

Figure 2

Table 2.Interrupted Time-Series Analysis of Oral Third-Generation Cephalosporins for Inpatients in 3 Groups

Figure 3

Fig 2.Segmented linear regression of oral third-generation cephalosporins (3GCs) days of therapy (DOT) per 1,000 outpatient visits among outpatients, before and after the targeted intervention. (A) All departments. (B) Ophthalmology. (C) Dermatology.

Figure 4

Table 3.Interrupted Time-Series Analysis of Oral Third-Generation Cephalosporins for Outpatients in 3 Groups

Figure 5

Table 4.Interrupted Time-Series Analysis for Hospital-wide Antimicrobial Consumption